Table 2. Lupus characteristics at baseline.
| Variable | Organ involvement with cSLE | cSLE-noNCD (N=9) | cSLE-NCD (N=6) |
|---|---|---|---|
| Disease duration (month) | 35.2 (28.0) | 28.6 (21.8) | |
| Disease activity (SLEDAIa) | 4.7 (3.3) | 11.3 (6.5) | |
| Mucocutaneous | 6 (66.7%) | 4 (66.7%) | |
| Neuropsychiatric | 0 (0%) | 1 (16.7%) | |
| Disease characteristicsb | Musculoskeletal | 5 (55.6%) | 4 (66.7%) |
| Renal | 2 (22.2%) | 3 (50.0%) | |
| Hematologic | 5 (55.6%) | 2 (33.3%) | |
| Disease damage (SDIc) | 0 (0) | 0.7 (1.2) | |
| Prednisone (mg/day) | 11.0 (6.3) | 33.6 (32.4) | |
| Azathioprine | 2 (22.2%) | 2 (33.3%) | |
| Cyclophosphamide | 0 (0%) | 1 (16.7%) | |
| Cyclosporine | 0 (0%) | 1 (16.7%) | |
| Immunosuppressive drugs | Methotrexate | 1 (11.1%) | 0 (0%) |
| Mycophenolate mofetil | 1 (11.1%) | 3 (50%) | |
| Rituximab | 0 (0%) | 0 (0%) | |
| Presence of anti-dsDNA Ab | 4 (44.4%) | 3 (50%) | |
| Hypocomplementemia | 8 (88.9%) | 3 (50%) | |
| Laboratory characteristicsd | Proteinuria (>0.5 g/24 hours) | 2 (22.2%) | 3 (50%) |
| Presence of anti-phospholipid Ab | 2 (22.2%) | 2 (33.3%) | |
| Presence of anti-ribosomal P Ab | 6 (66.6%) | 6 (100%) |
*
Values are mean (SD) unless stated differently.
a
Systemic Lupus Disease Activity Index 2k version; range 0-104; 0=inactive SLE.
b
Disease characteristics present if they were positive on SLEDAI or presence of A, B, or C category within the respective BILAG domain. No subjects with cardiac or gastrointestinal involvement.
c
Systemic Lupus Collaborative Clinics/American College of Rheumatology Damage Index.
d
Laboratory characteristics present if they were positive or met the SLEDAI definition for each laboratory test. No subjects with leukopenia (< 3,000) or thrombocytopenia (< 100,000).